Pure Green, LLC   Report issue

For profit Phase 2
Founded: Inkster MI United States (2018)
Status: No NME R&D (2018)

Organization Overview

First Clinical Trial
2019
NCT04088929
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Pure Green | Pure Green, LLC

Active Ingredients

Drugs in Phase 2 Trials (2)

cannabidiol (Epidiolex) (6 trials)

tetrahydrocannabinol (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Neuropathies (Phase 2)

Dysmenorrhea (Phase 2)

Fatigue (Phase 2)

Headache (Phase 2)

Migraine Disorders (Phase 2)

Musculoskeletal Pain (Phase 1)

Neuralgia (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 2